{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:54:35Z","timestamp":1783655675259,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ymgme.2025.109102","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T11:45:00Z","timestamp":1743767100000},"page":"109102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension"],"prefix":"10.1016","volume":"145","author":[{"given":"Uma","family":"Ramaswami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Font-Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damara","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarilis","family":"Sanchez-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester B.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Ann","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Vosk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2025.109102_bb0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2025.109102_bb0010","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2025.109102_bb0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria","volume":"51","author":"Tondel","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymgme.2025.109102_bb0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109102_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035182","article-title":"Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative","volume":"10","author":"Hughes","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ymgme.2025.109102_bb0030","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13023-022-02417-3","article-title":"Burden associated with Fabry disease and its treatment in 12\u201315 year olds: results from a European survey","volume":"17","author":"Bashorum","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109102_bb0035","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3390\/biom13081227","article-title":"Therapeutic role of pharmacological chaperones in lysosomal storage disorders: a review of the evidence and informed approach to reclassification","volume":"13","author":"Keyzor","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymgme.2025.109102_bb0040","article-title":"Clinical characteristics, renal involvement, and therapeutic options of pediatric patients with Fabry disease","volume":"10","author":"Muntean","year":"2022","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109102_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109102_bb0050","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/cpdd.1160","article-title":"Population pharmacokinetics of oral migalastat in adolescents and adults with and without renal impairment","volume":"11","author":"Leonowens","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ymgme.2025.109102_bb0055","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109102_bb0060","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.kint.2020.10.017","article-title":"Estimation of the glomerular filtration rate in children and young adults by means of the CKD-EPI equation with age-adjusted creatinine values","volume":"99","author":"Bjork","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2025.109102_bb0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1477-7525-10-116","article-title":"Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)","volume":"10","author":"Ramaswami","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.ymgme.2025.109102_bb0070","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1681\/ASN.2006050517","article-title":"Microalbuminuria as an early marker for cardiovascular disease","volume":"17","author":"de Zeeuw","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2025.109102_bb0075","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fped.2016.00106","article-title":"Changes in urine microalbumin-to-creatinine ratio in children with sickle cell disease over time","volume":"4","author":"Shatat","year":"2016","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109102_bb0080","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2025.109102_bb0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2025.109102_bb0090","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/jmg-2022-108669","article-title":"Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes","volume":"60","author":"Hughes","year":"2023","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2025.109102_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12771","article-title":"Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: results from the followME Fabry Pathfinders registry","volume":"48","author":"Hughes","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109102_bb0100","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2025.109102_bb0105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02186.x","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2025.109102_bb0110","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ekir.2023.07.028","article-title":"Changes in kidney function among Malaysian adolescents and its determinants","volume":"8","author":"Nawawi","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymgme.2025.109102_bb0115","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1007\/s00467-024-06435-0","article-title":"The evaluation of kidney function estimation during lifestyle intervention in children with overweight and obesity","volume":"39","author":"van Dam","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymgme.2025.109102_bb0120","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with Fabry disease: natural history data from the Fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2025.109102_bb0125","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2025.109102_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2025.109102_bb0135","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109102_bb0140","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak","year":"2022","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2025.109102_bb0145","doi-asserted-by":"crossref","first-page":"1220637","DOI":"10.3389\/fmed.2023.1220637","article-title":"Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study","volume":"10","author":"Bichet","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.ymgme.2025.109102_bb0150","doi-asserted-by":"crossref","DOI":"10.1177\/2326409816666298","article-title":"A 15-year perspective of the Fabry outcome survey","volume":"4","author":"Giugliani","year":"2016","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"10.1016\/j.ymgme.2025.109102_bb0155","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.3390\/ijerph18063320","article-title":"Gastrointestinal involvement in Anderson-Fabry disease: a narrative review","volume":"18","author":"Caputo","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.ymgme.2025.109102_bb0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109102_bb0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ymgme.2025.109102_bb0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-0036-1584357","article-title":"The psychosocial impact of Fabry disease on pediatric patients","volume":"5","author":"Bugescu","year":"2016","journal-title":"J. Pediatr. Genet."},{"key":"10.1016\/j.ymgme.2025.109102_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-7525-10-10","article-title":"The proxy problem anatomized: child-parent disagreement in health related quality of life reports of chronically ill adolescents","volume":"10","author":"Sattoe","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.ymgme.2025.109102_bb0180","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","article-title":"The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity","volume":"3","author":"Varni","year":"2003","journal-title":"Ambul. Pediatr."},{"key":"10.1016\/j.ymgme.2025.109102_bb0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00467-023-06050-5","article-title":"Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease","volume":"39","author":"Avarappattu","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymgme.2025.109102_bb0190","article-title":"The experiences of adolescents living with a central venous access device: a qualitative analysis","volume":"4","author":"Chimuris-Bautista","year":"2022","journal-title":"Int. J. Nurs. Stud. Adv."},{"key":"10.1016\/j.ymgme.2025.109102_bb0195","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2025.109102_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119843","article-title":"Fabry disease enzyme enhancement on migalastat study: FEES","volume":"561","author":"Kugan","year":"2024","journal-title":"Clin. Chim. Acta"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225000939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225000939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:42:09Z","timestamp":1771558929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225000939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1096719225000939"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109102","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109102"}}